NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: ROUNDTABLE

Several recent developments may provide an opportunity to improve outcome in individuals who develop neovascular age-related maculopathy (age-related macular degeneration [ARMD]). Concurrent with progress in isolating clinically relevant subtypes of neovascular ARMD, several therapies have been introduced that show promise for halting progression of this disorder. However, data from controlled clinical trials to test the relative efficacy of different management strategies across these subtypes of disease presentation remain limited. In addition, strategies to control ARMD may evolve quickly as more is learned about how specific molecular events, such as cell-mediated inflammation and angiogenesis, contribute to disease expression. A roundtable of investigators was convened to discuss and summarize recent progress in the treatment of ARMD. Case studies were then presented to provide an opportunity for experts to reveal their specific thought processes in the approach to neovascular ARMD based on their own interpretation of current clinical data and empirical experience.

[1]  K. Csaky,et al.  Clinical strategies for diagnosis and treatment of AMD: Implications from research , 2005 .

[2]  C. Curcio,et al.  Lipoprotein-like particles and cholesteryl esters in human Bruch's membrane: initial characterization. , 2005, Investigative ophthalmology & visual science.

[3]  W R Green,et al.  CLINICOPATHOLOGIC CORRELATION OF DRUSEN AND RETINAL PIGMENT EPITHELIAL ABNORMALITIES IN AGE-RELATED MACULAR DEGENERATION , 2005, Retina.

[4]  E. Sullivan,et al.  Reflux of Study Medication Affects the Clinical Outcomes of Anecortave Acetate for Depot Suspension in the Treatment of Patients With Exudative Age–Related Macular Degeneration (AMD) , 2005 .

[5]  A. Edwards,et al.  Complement Factor H Polymorphism and Age-Related Macular Degeneration , 2005, Science.

[6]  J. Ott,et al.  Complement Factor H Polymorphism in Age-Related Macular Degeneration , 2005, Science.

[7]  David J. Wilson,et al.  Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. , 2004, Ophthalmology.

[8]  Matthew A. Thomas,et al.  Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. , 2004, Ophthalmology.

[9]  R. Danis,et al.  Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome. , 2003, American journal of ophthalmology.

[10]  M. Farah,et al.  Indocyanine green-mediated photothrombosis combined with intravitreal triamcinolone for the treatment of choroidal neovascularization in serpiginous choroiditis , 2003, Eye.

[11]  S. Cousins,et al.  Smoking-Related Oxidants and RPE Injury In Vitro and In Vivo , 2003 .

[12]  Y. Nose,et al.  Risk factors for age related maculopathy in a Japanese population: the Hisayama study , 2003, The British journal of ophthalmology.

[13]  G. Vrensen,et al.  Vascular endothelial growth factors and angiogenesis in eye disease , 2003, Progress in Retinal and Eye Research.

[14]  Jennifer I. Lim.  Photodynamic therapy for choroidal neovascular disease: photosensitizers and clinical trials. , 2002, Ophthalmology clinics of North America.

[15]  K. Holroyd,et al.  EFFECT OF SQUALAMINE ON IRIS NEOVASCULARIZATION IN MONKEYS , 2002, Retina.

[16]  A. Lotery,et al.  Genetics update of macular diseases. , 2002, Ophthalmology clinics of North America.

[17]  R. Klein,et al.  Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study. , 2002, Ophthalmology.

[18]  Robert F Mullins,et al.  A role for local inflammation in the formation of drusen in the aging eye. , 2002, American journal of ophthalmology.

[19]  H. Grossniklaus,et al.  Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. , 2002, Molecular vision.

[20]  L. Singerman,et al.  Recent advances in the management of age-related macular degeneration. , 2002, Optometry and vision science : official publication of the American Academy of Optometry.

[21]  L. V. Johnson,et al.  Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. , 2001, Experimental eye research.

[22]  Robert F. Mullins,et al.  An Integrated Hypothesis That Considers Drusen as Biomarkers of Immune-Mediated Processes at the RPE-Bruch's Membrane Interface in Aging and Age-Related Macular Degeneration , 2001, Progress in Retinal and Eye Research.

[23]  J. Slakter,et al.  RETINAL ANGIOMATOUS PROLIFERATION IN AGE–RELATED MACULAR DEGENERATION , 2001, Retina.

[24]  R. Klein,et al.  The relation of socioeconomic factors to the incidence of early age-related maculopathy: the Beaver Dam eye study. , 2001, American journal of ophthalmology.

[25]  M. Gillies,et al.  Immunological and Aetiological Aspects of Macular Degeneration , 2001, Progress in Retinal and Eye Research.

[26]  M. Tamai,et al.  Macular degeneration associated with aberrant expansion of trinucleotide repeat of the SCA7 gene in 2 Japanese families. , 2000, Archives of ophthalmology.

[27]  M. Blumenkranz,et al.  Lutetium texaphyrin (Lu-Tex): a potential new agent for ocular fundus angiography and photodynamic therapy. , 2000, American journal of ophthalmology.

[28]  Greene Wr.  Histopathology of age-related macular degeneration. , 1999, Molecular vision.

[29]  R. Klein,et al.  Prevalence of age-related maculopathy in the Atherosclerosis Risk in Communities Study. , 1999, Archives of ophthalmology.

[30]  L. D. Del Priore,et al.  Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. , 1999, Survey of ophthalmology.

[31]  A Hofman,et al.  Genetic risk of age-related maculopathy. Population-based familial aggregation study. , 1998, Archives of ophthalmology.

[32]  B. Khoobehi,et al.  Ocular vascular thrombosis following tin ethyl etiopurpurin (SnET2) photodynamic therapy: time dependencies. , 1998, Ophthalmic surgery and lasers.

[33]  R J Glynn,et al.  A prospective study of cigarette smoking and risk of age-related macular degeneration in men. , 1996, JAMA.

[34]  J. J. Wang,et al.  Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. , 1995, Ophthalmology.

[35]  M. C. Leske,et al.  Features of Age-Related Macular Degeneration in a Black Population , 1995 .

[36]  R. Klein,et al.  Racial/ethnic differences in age-related maculopathy. Third National Health and Nutrition Examination Survey. , 1995, Ophthalmology.

[37]  J. Moisseiev,et al.  The impact of the macular photocoagulation study results on the treatment of exudative age-related macular degeneration. , 1995, Archives of ophthalmology.

[38]  Johannes R. Vingerling,et al.  The prevalence of age-related maculopathy in the Rotterdam Study. , 1995, Ophthalmology.

[39]  R Hiller,et al.  Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. , 1994, JAMA.

[40]  Lawrence A. Yannuzzi,et al.  Dietary Carotenoids, Vitamins A, C, and E, and Advanced Age-Related Macular Degeneration , 1994 .

[41]  Cord Sunderkötter,et al.  Macrophages and angiogenesis , 1994, Journal of leukocyte biology.

[42]  R. Klein,et al.  Prevalence of age-related maculopathy. The Beaver Dam Eye Study. , 1992, Ophthalmology.

[43]  R W Young,et al.  Pathophysiology of age-related macular degeneration. , 1987, Survey of ophthalmology.

[44]  J. Weiter,et al.  Relationship of senile macular degeneration to ocular pigmentation. , 1985, American journal of ophthalmology.

[45]  J. Provis,et al.  Age-related macular degeneration: ultrastructural studies of the relationship of leucocytes to angiogenesis , 2005, Graefe's Archive for Clinical and Experimental Ophthalmology.

[46]  A. Hendrickson,et al.  Organization of the Adult Primate Fovea , 2005 .

[47]  J. Provis,et al.  Immunology and Age-Related Macular Degeneration , 2005 .

[48]  L. Singerman,et al.  Natural history of subfoveal pigment epithelial detachments associated with subfoveal or unidentifiable choroidal neovascularization complicating age-related macular degeneration , 2005, Graefe's Archive for Clinical and Experimental Ophthalmology.

[49]  N. Bressler,et al.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. , 1999, Archives of ophthalmology.

[50]  R. Browne,et al.  Characterization of peroxidized lipids in Bruch's membrane. , 1999, Retina.

[51]  R. Klein,et al.  The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. , 1997, Ophthalmology.

[52]  R. Klein,et al.  The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. , 1995, Investigative ophthalmology & visual science.

[53]  A. Bird,et al.  Correlation between lipids extracted from Bruch's membrane and age. , 1993, Ophthalmology.

[54]  Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. , 1991, Archives of ophthalmology.

[55]  Hawkins.  Laser Photocoagulation of Subfoveal Recurrent Neovascular Lesions in Age-Related Macular Degeneration: Results of a Randomized Clinical Trial , 1991 .

[56]  Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group. , 1991, Archives of ophthalmology.

[57]  L. Singerman.  Laser photocoagulation for choroidal new vessel membrane complicating age-related macular degeneration associated with pigment epithelial detachment. , 1988, Retina.